Dexmedetomidine is under clinical development by BioXcel Therapeutics and currently in Phase I for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase I drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Dexmedetomidine LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexmedetomidine overview
Dexmedetomidine (Igalmi) is an imidazole derivate and active d-isomer of medetomidine with analgesic, anxiolytic and sedative properties. It is formulated as film for sublingual, buccal route of administration. Igalmi indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Dexmedetomidine is under development for the treatment of agitation in schizophrenia patients, bipolar patients, Alzheimer’s patients, haloperidol-refractory delirium patients, alcohol use disorder and opioid withdrawal symptoms and post traumatic stress disorder. The drug candidate is administered by sublingual route as thin film and through intravenous route. It acts by targeting selective alpha 2 adrenergic receptors. It is being developed based on artificial intelligence (AI) approach.
It was also under development for the treatment of major depressive disorder (MDD), agitation in geriatric dementia.
BioXcel Therapeutics overview
BioXcel Therapeutics is a commercial-stage biopharmaceutical company focused on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. The company pipeline product portfolio comprises BXCL501, an adrenergic agent with a sublingual route of administration targets neuropsychiatric and neurodegenerative diseases, BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers and BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders. BioXcel Therapeutics‘ drug re-innovation approach leverages existing approved drugs and clinically validated product candidates with big data and proprietary machine learning algorithms to develop new therapeutic candidates. BioXcel Therapeutics is headquartered in New Haven, Connecticut, the US.
For a complete picture of Dexmedetomidine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
